Tetragon Partners GP Ltd Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001515070

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallFocusedTechnology TiltHigh Turnover how tags are computed

Q2 2026 · 36 positions · Total reported value $613.69M · Top-10 concentration 76.6% · Updated 2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

Turnover: 42.5% · 6 new · 7 cut · 4 exited

Active Share (vs S&P 500): 99.9% · vs QQQ: 99.7% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q1 2026 → Q2 2026): +5.4% · vs SPY -9.5% · Prev Value $508.90M — last quarter positions weighted by this quarter price moves · ranking

In its Q2 2026 13F filing, Tetragon Partners GP Ltd disclosed 36 equity positions with a combined reported value of $613.69M. The filing implies a focused portfolio: its ten largest positions account for 76.6% of reported value. HoldingsHub classifies the profile as Small / Focused / Technology Tilt / High Turnover.

The largest disclosed positions as of Q2 2026 were PATH ($336.43M), KGEI ($33.85M), AUTL ($15.20M). By sector, the heaviest allocations are Technology 60.8%, Health Care 30.2%. Versus the prior quarter, allocation shifted toward Health Care (+6.6pp) and away from Other (-0.7pp), Energy (-1.9pp).

Versus the prior quarter, Tetragon Partners GP Ltd opened 6 new positions, trimmed 7 and fully exited 4, a turnover rate of 42.5% of positions. The portfolio's overlap with the prior quarter was 75% of names.

The largest new positions opened in Q2 2026 were ALKT ($10.88M), CELC ($6.71M), CUE ($2.96M).

Of the 4 positions fully exited versus the prior quarter, the largest were PRAX ($5.14M), SLNO ($3.42M), MPLT ($2.28M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q2 2026)

  • ALKT ALKAMI TECHNOLOGY INC · $10.88M
  • CELC CELCUITY INC · $6.71M
  • CUE CUE BIOPHARMA INC COM · $2.96M
  • ACRS ACLARIS THERAPEUTICS INC · $2.12M
  • GLUE MONTE ROSA THERAPEUTICS INC · $1.36M
  • TENX TENAX THERAPEUTICS INC · $1.09M

Fully Exited (vs previous quarter)

  • PRAX PRAXIS PRECISION MEDICINES I · prev qtr: $5.14M
  • SLNO SOLENO THERAPEUTICS INC · prev qtr: $3.42M
  • MPLT MAPLIGHT THERAPEUTICS INC · prev qtr: $2.28M
  • AARD Aardvark Therapeutics Inc · prev qtr: $1.19M

Insider Transactions (Form 4)

Latest Tetragon Partners GP Ltd buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Tetragon Partners GP Ltd files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q2 2026) lists 36 positions worth $613.69M in total. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Portfolio Structure

  • 36 positions · $613.69M reported value (Q2 2026)
  • Top 10 holdings = 76.6% of reported value
  • Largest position: PATH (UIPATH INC CL A) at 54.8%
  • Average position size: $17.05M

Sector Tilt

  • Information Technology 60.8%
  • Health Care 30.2%
  • Energy 5.5%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q2 2026: 6 new, 16 added, 7 reduced, 4 exited
  • 7 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall Direction and Market View: Tetragon Partners GP Ltd's latest quarter rebalancing seems to reflect a conservative approach with a preference for technology and health care sectors, suggesting a belief in long-term growth potential within these areas. 2. Key Moves: - Added: Uipath (PATH) by 22.8%, Definium Therapeutics (DFTX) by 43.5%, MBX Biosciences (MBX) by 39.9%, and Alkami Technology (ALKT) as a new holding. - Reduced: CellDex Therapeutics (CLDX) by 7.0%. - Held: Positions in Kolibri Global Energy (KGEI), Autolus Therapeutics (AUTL), Lyft (LYFT), Workiva (WK), Sprinklr (CXM), and others remained constant. 3. Portfolio Structure: - The portfolio appears to be actively managed, as evidenced by the additions and reductions in holdings. - The sector bias is toward technology and health care, indicating a focus on innovation and biotechnology. - The risk appetite seems moderate, with a balance between established companies (like Uipath) and smaller biotech firms (like DFTX and MBX). 4. Per-Holding One-Liner: - PATH (Uipath Inc): Enterprise software platform for robotic process automation (RPA). - KGEI (Kolibri Global Energy): Energy company focusing on global energy infrastructure and solutions. - AUTL (Autolus Therapeutics): Biopharmaceutical company specializing in cell therapies for cancer. - LYFT (Lyft Inc): Mobility company offering rideshare and other mobility services. - DFTX (Definium Therapeutics): Biotechnology company developing treatments for cancer. - WK (Workiva): Cloud-based platform for business reporting and compliance. - CXM (Sprinklr): Customer experience management platform. - MBX (MBX Biosciences): Biotechnology company focused on the development of cellular therapies. - ALKT (Alkami Technology): Technology company focusing on data analytics and AI solutions. - CLDX (CellDex Therapeutics): Biotechnology company developing treatments for cancer. 5. One-Sentence Style Summary: Tetragon Partners GP Ltd maintained a conservative yet proactive investment strategy in Q2 2026, adding to and reducing select holdings in technology and health care sectors, reflecting a belief in long-term growth potential and innovation.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice.

Sector Allocation

Technology 60.8%
Health Care 30.2%
Energy 5.5%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 30.95M $336.43M 54.82%
54.82%
Add
2 6.83M $33.85M 5.51%
5.51%
Hold
3 9.50M $15.20M 2.48%
2.48%
Hold
4 1.00M $14.61M 2.38%
2.38%
Hold
5 286.99K $13.50M 2.20%
2.20%
Add
6 250.00K $12.13M 1.98%
1.98%
Hold
7 2.20M $11.35M 1.85%
1.85%
Hold
8 203.54K $11.24M 1.83%
1.83%
Add
9 600.28K $10.88M 1.77%
1.77%
New
10 290.44K $10.81M 1.76%
1.76%
Reduce
11 570.31K $10.67M 1.74%
1.74%
Add
12 130.48K $10.64M 1.73%
1.73%
Add
13 295.63K $10.22M 1.67%
1.67%
Add
14 189.98K $9.95M 1.62%
1.62%
Add
15 255.93K $9.86M 1.61%
1.61%
Add
16 35.00K $8.57M 1.40%
1.40%
Add
17 356.66K $7.92M 1.29%
1.29%
Add
18 97.17K $7.70M 1.25%
1.25%
Add
19 201.04K $7.32M 1.19%
1.19%
Add
20 19.67K $7.31M 1.19%
1.19%
Hold
21 1.24M $7.09M 1.16%
1.16%
Reduce
22 64.11K $6.71M 1.09%
1.09%
New
23 250.00K $6.67M 1.09%
1.09%
Reduce
24 87.00K $6.07M 0.99%
0.99%
Reduce
25 167.88K $4.25M 0.69%
0.69%
Add
26 100.00K $3.34M 0.54%
0.54%
Add
27 300.00K $3.29M 0.54%
0.54%
Reduce
28 93.82K $2.96M 0.48%
0.48%
New
29 10.00K $2.54M 0.41%
0.41%
Hold
30 250.30K $2.45M 0.40%
0.40%
Add
31 400.00K $2.12M 0.34%
0.34%
New
32 50.00K $1.86M 0.30%
0.30%
Reduce
33 46.52K $1.60M 0.26%
0.26%
Add
34 56.05K $1.36M 0.22%
0.22%
New
35 75.10K $1.09M 0.18%
0.18%
New
36 8.50K $152.66K 0.03%
0.03%
Reduce

Holdings Prediction Model

Predicts next-quarter Top-10 holdings and weights from the fund's own historical trading轨迹 (add / reduce / hold) plus each stock's price momentum and relative volume. Strictly no look-ahead: a prediction for quarter T+1 uses only data through quarter T. Weights are shares of the modelled portfolio.

The next-quarter predicted Top 10 (2026-Q3) is shown in the «Latest Q · Forecast» tab above, in the same holdings format. That view is for logged-in accounts: 3 views per day on Free, unlimited on Gold/Diamond.

Latest-Quarter Accuracy (2026-Q2)

P 70% R 70% F1 70% (modelled on 2026-Q1; 7/10 hit)

Low-confidence forecast This fund replaces about 23% of its Top-10 each quarter and backtests at F1 78% (threshold 80%). Holdings in high-turnover portfolios cannot be forecast from their own history; the figures below are illustrative.

Historical Backtest (10 quarters)

Avg precision 78% · recall 78% · F1 78% · avg rank error 2.4 · Top-10 turnover 23%

Quarter Prec. Recall F1 Predicted Top 10 Actual Top 10
2024-Q1 80% 80% 80% PATH · AUTL · LYFT · CXM · TAK · KGEI · BALY · AYX · CYTK · TARS PATH · AUTL · CYTK · AG · CXM · KGEI · BALY · TARS · SSRM · LYFT
2024-Q2 100% 100% 100% PATH · AUTL · AG · CYTK · CXM · KGEI · BALY · TARS · SSRM · LYFT PATH · AG · AUTL · KGEI · CXM · CYTK · BALY · LYFT · TARS · SSRM
2024-Q3 80% 80% 80% PATH · AG · AUTL · KGEI · CXM · CYTK · BALY · LYFT · TARS · SSRM PATH · AG · AUTL · KGEI · TARS · SSRM · CXM · LYFT · OTLY · INFA
2024-Q4 100% 100% 100% PATH · AG · AUTL · KGEI · TARS · SSRM · CXM · LYFT · OTLY · INFA PATH · KGEI · AUTL · SSRM · CXM · INFA · OTLY · AG · LYFT · TARS
2025-Q1 80% 80% 80% PATH · KGEI · SSRM · AUTL · CXM · INFA · OTLY · AG · LYFT · TARS PATH · KGEI · LAR · CXM · AG · INFA · AUTL · LYFT · TARS · CYTK
2025-Q2 60% 60% 60% PATH · KGEI · LAR · CXM · INFA · AG · AUTL · LYFT · TARS · ANNX PATH · BABA · KGEI · AUTL · JD · CXM · LYFT · LAR · OTLY · TCOM
2025-Q3 70% 70% 70% PATH · BABA · KGEI · AUTL · JD · CXM · OTLY · LYFT · LAR · TCOM PATH · BABA · KGEI · LYFT · CABO · PRGS · OTLY · CXM · AUTL · WK
2025-Q4 60% 60% 60% PATH · BABA · KGEI · PRGS · LYFT · OTLY · CABO · CXM · AUTL · WK PATH · KGEI · LYFT · AUTL · CXM · WK · ANNX · PRAX · CLDX · ARWR
2026-Q1 80% 80% 80% PATH · KGEI · LYFT · AUTL · CXM · WK · ANNX · PRAX · ARWR · CLDX PATH · KGEI · WBD · WK · LYFT · CXM · AUTL · CLDX · ARWR · NKTR
2026-Q2 ★ 70% 70% 70% PATH · KGEI · WBD · WK · LYFT · CXM · AUTL · CLDX · ARWR · NKTR PATH · KGEI · AUTL · LYFT · DFTX · WK · CXM · MBX · ALKT · CLDX

★ = latest filed quarter (predicted vs actual). Recall = share of the real Top 10 caught by the model; precision = share of the predicted Top 10 that were real.

FAQ

What did Tetragon Partners GP Ltd buy in 2026-Q2?

In its 2026-Q2 13F filing, Tetragon Partners GP Ltd reported 36 equity positions worth $613.69M in aggregate; its largest disclosed positions were PATH ($336.43M), KGEI ($33.85M), AUTL ($15.20M).

How large is Tetragon Partners GP Ltd's portfolio?

Tetragon Partners GP Ltd reported $613.69M of long equity holdings across 36 positions as of 2026-Q2. Top-10 holdings account for 76.6% of reported value.

What is Tetragon Partners GP Ltd's investment style?

HoldingsHub classifies the portfolio as Small / Focused / Technology Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/tetragon-partners-gp/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →